These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30187454)

  • 1. Misinterpretation of blood group and antibody screen leading to serious errors in RhD immunoglobulin administration: A report on first two years of data from Serious Transfusion Incident Reporting program.
    Akers C; Savoia H; Kane S; Crispin P; Keegan A; Wood E; Glazebrook B; Bielby L; Davis AK
    Aust N Z J Obstet Gynaecol; 2019 Feb; 59(1):161-164. PubMed ID: 30187454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring the clearance of fetal RhD-positive red cells in FMH following RhD immunoglobulin administration.
    Lubenko A; Williams M; Johnson A; Pluck J; Armstrong D; MacLennan S
    Transfus Med; 1999 Dec; 9(4):331-5. PubMed ID: 10583887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme.
    Bolton-Maggs PH; Davies T; Poles D; Cohen H
    BJOG; 2013 Jun; 120(7):873-8. PubMed ID: 23489292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Spontaneous antepartal RhD alloimmunization].
    Studničková M; Holusková I; Durdová V; Kratochvílová T; Strašilová P; Marková I; Lubušký M
    Ceska Gynekol; 2015 Dec; 80(6):401-4. PubMed ID: 26741153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal red blood cell alloimmunisation in south western Uganda.
    Natukunda B; Mugyenyi G; Brand A; Schonewille H
    Transfus Med; 2011 Aug; 21(4):262-6. PubMed ID: 21371143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practices and outcomes of RhD immunoglobulin prophylaxis following large-volume fetomaternal haemorrhage in Queensland, Australia.
    Tneh SY; Baidya S; Daly J
    Aust N Z J Obstet Gynaecol; 2021 Apr; 61(2):205-212. PubMed ID: 32789858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-D alloimmunisation in pregnant women with DEL phenotype in China.
    Wang M; Wang BL; Xu W; Fan DD; Peng ML; Pan J; Yao P; Jiang GM; Wan XJ
    Transfus Med; 2015 Jun; 25(3):163-9. PubMed ID: 26033335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current trends in immunoprophylaxis of anti-Rho isoimmunization].
    Sirchia G; Mercuriali F
    Clin Ter; 1970 Feb; 52(4):385-90. PubMed ID: 5005934
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prevention of maternal isoimmunization to RhD antigen].
    Baptista González HA; Rosenfeld Mann F
    Salud Publica Mex; 2004; 46(3):194-5; author reply 196-7. PubMed ID: 15368858
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy.
    Koelewijn JM; Vrijkotte TG; de Haas M; van der Schoot CE; Bonsel GJ
    BJOG; 2009 Apr; 116(5):655-64. PubMed ID: 19210505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibility to identify fetomaternal haemorrhage].
    Studnicková M; L'ubuský M; Ordeltová M; Procházka M
    Ceska Gynekol; 2010 Oct; 75(5):443-6. PubMed ID: 21374922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The scientific basis of antenatal prophylaxis.
    Urbaniak SJ
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():11-8. PubMed ID: 9863973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention.
    Denomme GA; Wagner FF; Fernandes BJ; Li W; Flegel WA
    Transfusion; 2005 Oct; 45(10):1554-60. PubMed ID: 16181204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guideline for prevention of RhD alloimmunizationin RhD negative women].
    Lubušký M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality audit of the guidelines for the use of RhD immunoglobulin in obstetrics: Are we getting it right?
    Glazebrook B; Akers C; Bielby L; Bastin K; Von Wielligh K; Daly J
    Aust N Z J Obstet Gynaecol; 2020 Aug; 60(4):504-508. PubMed ID: 32424867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of prenatal determination of RhD type status by polymerase chain reaction with amniotic cells.
    Lighten AD; Overton TG; Sepulveda W; Warwick RM; Fisk NM; Bennett PR
    Am J Obstet Gynecol; 1995 Oct; 173(4):1182-5. PubMed ID: 7485316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pregnant Rhesus negative Nigerian woman.
    Kotila TR; Odukogbe AA; Okunlola MA; Olayemi O; Obisesan KA
    Niger Postgrad Med J; 2005 Dec; 12(4):305-7. PubMed ID: 16380744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients.
    Ben-David G; Sheiner E; Levy A; Erez O; Mazor M
    J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The issue of anti-D: an integrated seamless approach from recognition of need to bedside administration.
    Ryan MJ; Joyce S; O'Brien N; Lynch E; Burke G; Cahill MR
    Ir J Med Sci; 2005; 174(3):58-63. PubMed ID: 16285341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.